Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veteran… (NCT06399653) | Clinical Trial Compass
RecruitingNot Applicable
Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder
United States80 participantsStarted 2025-01-01
Plain-language summary
Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes functional impairments and decreased quality of life. Current AUD treatments show limited effectiveness in reducing withdrawal-related psychological and physical distress, which drives the urge to drink to relieve these symptoms. The investigators propose the vagus nerve, which is the primary nerve of the "rest and digest" branch of the autonomic nervous system via its bidirectional connections between the brain and the body, as a novel treatment target for AUD. The goal of this study is to assess treatment efficacy and mechanism of action. Noninvasive neuromodulation technologies offer the possibility for innovative, low risk treatments to support the rehabilitation and community reintegration of Veterans with AUD.
Who can participate
Age range21 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Veterans between 21 and 65 years, any race or ethnicity.
✓. Meet current DSM-5 diagnosis of moderate or severe AUD (Structured Clinical Interview for DMS-5 (SCID) interview) with at least one functional disability due to alcohol use, current alcohol craving, and current heavy drinking (\>= 5 drinks (men) / \>= 4 drinks (women) on the same occasion, on 5 or more days in the past month) as defined by the Substance Abuse and Mental Health Services Administration (SAMHSA), and mild to moderate withdrawal symptoms during abstinence.
✓. Able to forgo consumption of alcohol for 12-24 hours without any serious discomfort or complications.
✓. Capable of complying with study schedule, procedures, and speaks English.
✓. Able to provide voluntary written informed consent prior to initiation of visit 1.
✓. Able and willing to self-administer nVNS/sham stimulation as instructed for the duration of the study, and willing to commit to the return visit at the end of the study.
Exclusion criteria
✕. Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) score \>10 on the day of the scan (symptoms judged to be due to co-existing anxiety or headache disorders will not be counted toward the total).
What they're measuring
1
Hamilton Anxiety Rating Scale (HAM-A)
Timeframe: Baseline to week 1 and 1 month post baseline of 2x daily intervention
2
Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)
Timeframe: Baseline to week 1 and 1 month post baseline of 2x daily intervention
3
Alcohol Urge Questionnaire (AUQ)
Timeframe: Baseline to week 1 and 1 month post baseline of 2x daily intervention
4
WHO Quality of Life assessment (WHOQOL-BREF)
Timeframe: Baseline to week 1 and 1 month post baseline of 2x daily intervention
✕. Recent history past 6 months) of severe complications due to alcohol withdrawal (alcohol withdrawal seizures, hallucinations/illusions, delirium tremens).
✕. Currently or recently (within last 90 days) enrolled in abstinence-based treatment program.
✕. Evidence of a maladaptive pattern of substance use or abuse other than alcohol one month prior to screening visit.
✕. Uncontrolled severe psychiatric disorder with psychotic symptoms or cognitive impairment. We will not exclude for PTSD.
✕. At risk for suicide requiring urgent higher-level care or homicide (based on the Columbia-Suicide Severity Rating Scale and follow-up clinical interview).
✕. History of neurological disorder that might be associated with cognitive dysfunction.
✕. History of head trauma involving loss of consciousness \>24 hours